Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti's Micro-Cap Virtual Investor Conference taking place May 20-21, 2026. The company's presentation is scheduled to begin at 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one investor meetings planned throughout the conference, according to a press release.
Oragenics is developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company is advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury (mTBI). Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The Sidoti Micro-Cap Virtual Investor Conference provides a platform for emerging growth companies to connect with institutional investors, analysts, and other financial professionals. For Oragenics, this presentation offers an opportunity to update the investment community on its clinical development plans and the potential of its intranasal delivery technology to address significant unmet medical needs in neurological care.
Concussion and mild traumatic brain injury affect millions of people worldwide each year, yet there are currently no FDA-approved treatments specifically for these conditions. ONP-002 aims to fill this gap by delivering a neuroprotective agent directly to the brain via the nasal cavity, bypassing the blood-brain barrier and potentially reducing side effects associated with systemic administration. If successful, ONP-002 could become a first-in-class therapy, offering new hope for patients suffering from the acute and long-term effects of concussion.
The implications for the industry are substantial. A successful Phase 2b trial in the U.S. would not only validate Oragenics' intranasal delivery platform but also pave the way for a new class of neurological treatments. The platform's versatility could be applied to other central nervous system disorders, potentially expanding the company's pipeline and market opportunities. For investors, the Sidoti conference represents a chance to gauge the company's progress and the commercial potential of its technology.
Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. The company's presentation at the Sidoti conference underscores its efforts to engage with the investment community as it advances toward key clinical milestones. For more information about Oragenics, visit the company's website at oragenics.com.
The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN. To view the full press release, visit https://ibn.fm/MLd0Y.
